yl201
mAbexperimentalADC
Clinical trial activity
9 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Jun 9, 2022 (NCT05434234)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07258979 | Phase 1/Phase 2 (Phase 2) | Nov 5, 2025 | Suzhou Medilink Therapeutics Ltd. |
| NCT07208773 | Phase 1/Phase 2 (Phase 2) | Oct 29, 2025 | Akeso Pharmaceuticals, Inc., Suzhou Medilink Therapeutics Ltd. |
| NCT06898957 | Phase 1 | May 16, 2025 | Amgen |
| NCT06612151 | Phase 3 | Dec 1, 2024 | Suzhou Medilink Therapeutics Ltd. |
| NCT06629597 | Phase 3 | Dec 1, 2024 | Suzhou Medilink Therapeutics Ltd. |
| NCT06394414 | Phase 1 | Apr 17, 2024 | Suzhou Medilink Therapeutics Ltd. |
| NCT06241846 | Phase 2 | Feb 22, 2024 | Suzhou Medilink Therapeutics Ltd. |
| NCT06057922 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2023 | Suzhou Medilink Therapeutics Ltd. |
| NCT05434234 | Phase 1 | Jun 9, 2022 | Suzhou Medilink Therapeutics Ltd. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Medilink Therapeutics Ltd. | For profit | 8 | 8 | 3 | 2022 |
| Akeso Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2025 |
| Amgen | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1